Novo Nordisk stock reversed a three-day downtrend Wednesday after the weight-loss drugs kingpin leaned on Ozempic for a fourth-quarter beat.
During the December quarter, Ozempic sales climbed 7% to $4.71 billion, according to FactSet. That topped the Street's call for $4.59 billion. Wegovy, on the other hand, generated $2.77 billion in sales, rocketing more than 97% year over year. But Wegovy sales missed forecasts for $2.78 billion. Wegovy uses the same semaglutide chemical backbone as Ozempic.
Still, the drugmaker called for "continued periodic supply constraints and related drug shortage notifications" in its 2025 outlook. For the year, Novo Nordisk expects sales to rise 16% to 24% in constant currency. The Food and Drug Administration says semaglutide is currently in shortage, but lists every form of Ozempic and Wegovy injections as being available.
On today's stock market, Novo Nordisk stock jumped 3.8%, closing at 85.73.
Novo Nordisk Stock: Earnings, Sales Beat
Across all its products, Novo Nordisk came in with $11.92 billion in fourth-quarter sales, according to FactSet, which translates Novo's report from Danish kroner to U.S. dollars. On a strict, as-reported basis, sales climbed almost 23%. Analysts projected $11.14 billion in sales.
Novo also reported adjusted earnings of 88 cents per share. Earnings jumped more than 22% vs. the year-ago period, and beat forecasts by a nickel per share.
Novo Nordisk stock is now making its way back toward its 50-day line, MarketSurge shows. Shares have mostly traded below that moving average since September.
